Navigation Links
DURECT Reports Data From European Phase IIb Hysterectomy Study of POSIDUR(TM) (SABER(TM)-Bupivacaine)
Date:6/16/2010

emarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

DURECT Forward-Looking Statement

The statements in this press release regarding the potential uses and benefits of POSIDUR, indications of clinical efficacy and safety of POSIDUR, the design of BESST and overall NDA strategy and possible royalties and milestone payments receivable from our collaborations with Nycomed and Hospira are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements.  Potential risks and uncertainties include, but are not limited to, our and our collaborators' difficulty or failure to obtain approvals from regulatory agencies with respect to clinical trials and other development activities, or  design, enroll, conduct and complete clinical trials, failure of such clinical trials to produce intended results or to confirm results from earlier clinical trials, possible adverse events associated with the use of POSIDUR, delays and costs due to additional work or other requirements imposed by regulatory agencies for continued development, approval or sale of POSIDUR, our ability to complete the design, development, and manufacturing process development of POSIDUR, and to manufacture, commercialize and obtain marketplace acceptance of POSIDUR, and avoid infringing patents held by other parties and secure and defend patents of our own, and manage and obtain capital to fund our growth, operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-Q filed on May 10, 2010 under the heading "Risk Factors."


'/>"/>
SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. DURECT Announces Positive ELADUR(TM) Phase IIa Study Results
2. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
3. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
4. DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
5. DURECT to Present at the 21st Annual Piper Jaffray Health Care Conference
6. DURECT Corporation Invites You to Join Its Fourth Quarter 2009 Earnings Conference Call
7. DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory
8. DURECT Corporation Announces Fourth Quarter and Year End 2009 Financial Results
9. DURECT to Present at the Cowen and Company Healthcare Conference
10. DURECT to Present at the Barclays Capital Global Healthcare Conference
11. DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... NEW YORK and LONDON ... distributor of market intelligence, MarketResearch.com is pleased to announce ... Research and Consultancy focusing on the active pharmaceutical ingredient ... Research visit: http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . In ... Market – Forecast to 2020 , ...
(Date:11/26/2014)... , Nov. 25, 2014  goBalto, Inc., the ... been recognized as a winner of Red Herring,s ... Global Top 100 North America award in 2013, marking ... technology landscape. Red Herring,s Top 100 Global ... promising new companies and entrepreneurs. Red Herring editors were ...
(Date:11/26/2014)... , Nov. 25, 2014 Nanomix ... on the development of mobile diagnostic tests ... in hospital and pre-hospital settings, today announced ... 13485:2003 certification.  The certification was awarded by ... the world,s leading certification bodies. ...
Breaking Medicine Technology:MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3goBalto Selected as a 2014 Red Herring Top 100 Global Company 2goBalto Selected as a 2014 Red Herring Top 100 Global Company 3Nanomix Receives ISO 13485:2003 Certification 2
... DIEGO, Oct. 26 The ... Circle at their Annual Scientific Meeting, becoming the first medical association ... collaborative community. Meeting attendees, authors and presenters can, for the ... latest breakthroughs in clinical gastroenterology during -- and well after -- ...
... 26 Sequenom, Inc. (Nasdaq: SQNM ), today ... the company,s interim chief financial officer effective November 10, ... officer and chairman of the board, Harry F. Hixson, ... Prior to the effective date of Mr. Maier,s appointment ...
Cached Medicine Technology:American College of Gastroenterology to Revolutionize Scientific Exchange on Within3 2American College of Gastroenterology to Revolutionize Scientific Exchange on Within3 3Sequenom Announces Paul Maier to Become Interim Chief Financial Officer 2Sequenom Announces Paul Maier to Become Interim Chief Financial Officer 3
(Date:11/27/2014)... Cambrionix Ltd today announced that it ranked number 10 in ... 50 fastest-growing technology companies in the UK. Rankings are ... Cambrionix Ltd grew 2989 percent during this period. ... Cambridgeshire and East and first in the sector of Electronics. ... of the hard work put in by our team who ...
(Date:11/27/2014)... 27, 2014 Blood-borne pathogens raise the ... precautions and procedures in place to counter this. However, ... of things tainted with menstrual blood are taken as ... simpler, more sanitary way to handle tampons and menstrual ... from Sonora, Calif. , He then created a prototype ...
(Date:11/27/2014)... PA (PRWEB) November 27, 2014 "As ... the embarrassing side effects of urinary incontinence," said an ... it and developed this specialized accessory to prevent leakage ... the Incontinence to absorb urine leakage. This prevents stains ... from potential embarrassment. The pad ensures that the individual ...
(Date:11/27/2014)... By Randy Dotinga ... -- Some people,s brains seem pre-wired to acquire a second ... beyond their mother tongue will likely gain a brain boost, ... connected and integrated after learning," said study co-author Ping Li, ... Pennsylvania State University. But it,s even more interesting, Li said, ...
(Date:11/27/2014)... HealthDay Reporter WEDNESDAY, Nov. ... to be safe and produces an immune system response that ... clinical trial results reported by the U.S. National Institutes of ... for the vaccine paves the way for field-testing it in ... as early as January, said Dr. Anthony Fauci, director of ...
Breaking Medicine News(10 mins):Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 2Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 3Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 4Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3
... of prostate cancer is common among older men. Being the ... it is the second leading cause of cancer deaths in ... been a increase in number of detected cases. Most men ... and a prostate-specific antigen (PSA) blood test. In rectal exam ...
... found that women with breast cancer are more likely ... blood. A residue of the fungicide hexachlorobenzene (HCB) were ... that DDT or HCB actually cause breast cancer. The ... for mosquito control in developing countries. DDT, HCB and ...
... a study drinking tea on regular basis help protect ... an increased rate of survival following a heart attack.,Researchers ... group of antioxidants known as,flavonoids, which are plentiful in ... in certain fruits and vegetables, including apples, onions, and ...
... found that evening administration of the central alpha(2)-agonists ... in the morning in hypertensive patients. The study ... to receive once-daily evening administration of guanabenz or ... effects of the two drugs in the morning ...
... Researchers at an American university have found that ... chemical. When one chew broccoli, its cells rupture ... sulphoraphanes. To simulate chewing the researchers crushed raw ... Researchers said that broccoli obtained from common supermarket ...
... question of whether daily moderate exercise could actually prevent ... like jogging, hiking, climbing stairs, racket sports and swimming ... from heart disease. Recommendations in the United States and ... walking, is sufficient for good heart health.// A World ...
Cached Medicine News:
... use. Kit comprises: 1 Miller 0 Premature; 1 Miller ... Ad.; 1 Mac 2 Child; 1 Mac 3 Medium ... Standard, 1 Nylon Carrying Case. The Lite Blade Kit ... take your disposable laryngoscopes anywhere. Each blade and handle ...
... The Flipper® is a unique fiberoptic ... bit of anterior exposure sometimes needed during ... the end of the blade to be ... the handle. This one-handed operation produces a ...
... fiberoptic Naso-Pharyngo-Laryngoscope provides a new standard in ... latest in Fujinon engineering combines high resolution ... a wide 90 degree field of view ... diameter. In addition, the FR-120F offers ...
... CCR Medical's Articulating Tip Laryngoscopes ... in the Industry. The articulating ... by providing an improved view ... and Fiber Optic styles. We ...
Medicine Products: